US Stock MarketDetailed Quotes
ICCM Icecure Medical
- 0.832
- +0.046+5.82%
Close Nov 27 16:00 ET
46.19MMarket Cap-2972P/E (TTM)
0.850High0.780Low547.59KVolume0.780Open0.786Pre Close449.25KTurnover1.95%Turnover RatioLossP/E (Static)55.50MShares1.57052wk High4.60P/B23.34MFloat Cap0.48052wk Low--Dividend TTM28.04MShs Float16.000Historical High--Div YieldTTM8.90%Amplitude0.480Historical Low0.820Avg Price1Lot Size
Icecure Medical Stock Forum
Sign in to post a comment
$HWH International (HWH.US)$ 13D 88.9%. China stock. Low float. SI 214%✅
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
35
20
$Icecure Medical (ICCM.US)$ Financial Performance:
ProSense systems and disposable probe sales increased by 36% to $2.32 million for the nine months ending September 30, 2024, compared to the previous year.
Total revenue grew by 22% to $2.42 million in the same period, driven by higher sales in Europe, the US, and Japan.
Gross profit increased by 41% to $1.03 million, an...
ProSense systems and disposable probe sales increased by 36% to $2.32 million for the nine months ending September 30, 2024, compared to the previous year.
Total revenue grew by 22% to $2.42 million in the same period, driven by higher sales in Europe, the US, and Japan.
Gross profit increased by 41% to $1.03 million, an...
1
$Icecure Medical (ICCM.US)$
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
IceCure Medical reported strong financial results for the first nine months of 2024, with 36% growth in ProSense® system and probe sales to $2.3M.
Gross profits increased 41%, with non-GAAP gross profits up 104%.
Gross margins improved to 43% from 37% year-over-year.
The FDA Advisory Panel voted favorably for ProSense®'s benefit-risk prof...
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
IceCure Medical reported strong financial results for the first nine months of 2024, with 36% growth in ProSense® system and probe sales to $2.3M.
Gross profits increased 41%, with non-GAAP gross profits up 104%.
Gross margins improved to 43% from 37% year-over-year.
The FDA Advisory Panel voted favorably for ProSense®'s benefit-risk prof...
2
1
I WILL UPDATE IF I FIND MORE
$Poseida Therapeutics (PSTX.US)$ ✔️TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$✔️ News halt after hours + PR today o...
$Poseida Therapeutics (PSTX.US)$ ✔️TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$✔️ News halt after hours + PR today o...
40
11
$Icecure Medical (ICCM.US)$
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
IceCure Medical (NASDAQ: ICCM) has received a Notice of Allowance from Japan's Patent Office for its 'Cryogenic System with Multiple Submerged Pumps' invention. This technology enables a next-generation MSense™ multiprobe cryoablation system that can independently control multiple cryoprobes for treating larger tumors. The patent strengthens IceCure's ...
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
IceCure Medical (NASDAQ: ICCM) has received a Notice of Allowance from Japan's Patent Office for its 'Cryogenic System with Multiple Submerged Pumps' invention. This technology enables a next-generation MSense™ multiprobe cryoablation system that can independently control multiple cryoprobes for treating larger tumors. The patent strengthens IceCure's ...
1
1
$Icecure Medical (ICCM.US)$ Reuters· 1 min ago
Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office
Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office
$Icecure Medical (ICCM.US)$ IceCure's ProSense Chosen For Breast Cryoablation Study Led By The European Institute Of Oncology With Sponsorship From The Italian Ministry Of Health
Benzinga· 3 mins ago
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists
PRECICE is exclusively using ProSense to treat all 233 Lu...
Benzinga· 3 mins ago
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists
PRECICE is exclusively using ProSense to treat all 233 Lu...
$Icecure Medical (ICCM.US)$
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
IceCure Medical's ProSense® has been selected for the PRECICE study, a major breast cryoablation research initiative led by the European Institute of Oncology. The study, sponsored by the Umberto Veronesi Foundation and Italian Ministry of Health, will exclusively use ProSense® to treat 233 patients aged...
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
IceCure Medical's ProSense® has been selected for the PRECICE study, a major breast cryoablation research initiative led by the European Institute of Oncology. The study, sponsored by the Umberto Veronesi Foundation and Italian Ministry of Health, will exclusively use ProSense® to treat 233 patients aged...
$Icecure Medical (ICCM.US)$ Reuters
1 min ago
FDA Advisory Panel Votes in Favor of Icecure's Prosense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
1 min ago
FDA Advisory Panel Votes in Favor of Icecure's Prosense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
3
$Volato Group (SOAR.US)$ $Toast (TOST.US)$ $Upstart (UPST.US)$ $Icecure Medical (ICCM.US)$ $Five9 (FIVN.US)$ $Lumentum (LITE.US)$ $Nature's Miracle (NMHI.US)$ $Innodata (INOD.US)$ $Northann (NCL.US)$ $LI-CYCLE (LICY.US)$ $Doximity (DOCS.US)$ $Tivic Health Systems (TIVC.US)$ $DevvStream (DEVS.US)$
📊⚡️📊
📊⚡️📊
6
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Moni Moni Moo : may i know what mean 0% LTB?
Jaguar8 OP Moni Moni Moo : 0 short shares left to borrow
msaf79 : Thanks @Jaguar8
103732118 : Hi. PTIX.US will be delisted this Friday? After delist ed its shares cannot be traded in moomo? Thx.
Jaguar8 OP 103732118 : It needs to file appeal tomorrow. If there is no news of filing appeal tomorrow, then it will delist and may likely go to OTC
View more comments...